Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
STATEN ISLAND, N.Y., Jan. 29, 2024 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced positive extended clinical cure (ECC) data for ibezapolstat (IBZ), its lead antibiotic candidate, from the Company’s recently completed Phase 2b clinical trial in patients with CDI. This exploratory endpoint showed that 12 patients who agreed to be followed up to three months following Clinical Cure of their infection, 5 of 5 IBZ patients experienced no recurrence of infection. In the vancomycin control arm of the trial, 7 of 7 patients experienced no recurrence of infection. ECC success is defined as a clinical cure at the TOC visit (i.e., at least 48 hours post EOT) and no recurrence of CDI within the 56 ± 2 days post EOT (ECC56) and 84 ± 2 days post EOT (ECC84) in patients who consented to extended observation.
Related news for (ACXP)
- Morning Market Brief: Biotech Names Stir as VENU Rockets on FireSuite Sales
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/08/25 04:00 AM
- MoBot alert highlights: NASDAQ: ACXP, NASDAQ: PCSA, NASDAQ: SLRX, NASDAQ: XTLB, NYSE: BURU (10/07/25 06:00 PM)
- Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
- Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split